PDCD1 and Hodgkins lymphoma: According to the present study, we explored the effect of BMI on ORR considering that, on one hand, HL patients usually had a long survival including in those relapsed/refractory HL patients with the development of new drugs like programmed cell death protein 1 (PD-1) inhibitors, CD30 inhibitors; on the other hand, ORR may translate to improved survival with a long follow-up period (Ma et al., 2021).